The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

New Delhi: In its latest drug alert, the apex drug regulatory body, the Central Drug Standard Control Organization (CDSCO), ...

As many as 38 drug samples manufactured in various drug clusters of the state failed quality parameters in the monthly alert ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals i ...

The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...

Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...